Disclaimer: This image is entirely AI-generated and is a product of artificial intelligence. Any resemblance to actual persons, whether living or deceased, is purely coincidental and unintentional.
Uploaded 3 months ago
Duration: 0h 3m 14s
Biocon launches diabetes & obesity drugs in Netherlands
Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the fast-growing diabetes and obesity market currently dominated by the likes of Novo Nordisk and Eli Lilly.
Uploaded by: Rediff Video Desk on Tue, 16 Dec 2025 11:49:53 +0530
Views: 18
Tags: Biocon launches diabetes & obesity drugs in Netherlands
© 2026